Benchmarking reveals PreciseInhale best-in-class

  • 5 december, 2013
  • 15:54

What sets PreciseInhale, Inhalation Sciences’ precision dosing system, apart from its competitors? New benchmarking reveals the history and benefits of the system that is currently rolling out its first major sales.

Benchmarking PreciseInhale against competing technologies, reveals significant quality and cost benefits. This reflects the new way of thinking about aerosol methodology that underpins the platform. Dr. Per Gerde, inventor of the system and founder of Inhalation Sciences, explains:

“Historically, the main focus of most aerosol distribution technologies has been on maintaining a constant aerosol concentration for the simultaneous exposure of groups of animals.  With PreciseInhale the focus is on the inhaled dose in the lungs, as determined both by the aerosol concentration and the breathing pattern of the exposed animal. From the beginning we therefore aimed for active dosing of the test compound.”

inhalation-tables-1

Two units produce very fine aerosol exposures

Unlike all other solutions, the PreciseInhale platform separates the process of aerosol exposures into the consecutive steps of aerosol generation and aerosol dispensing – integrated into the one platform. This allows the high energy released during aerosolization to be separated from the exposures of delicate lungs. The generator de-agglomerates dry powders into very fine, and narrowly-sized powder aerosols – with exceptionally low standard deviation between repeated experiments. The result is high-quality results even from small amounts of test substance.

“PreciseInhale generates a very fine powder aerosol evenly delivered, providing high-quality results. With many other systems you lose individual control due to multiple animal exposures so the dose can be difficult to regulate. And because of the lower energy employed during most other aerosol generation methods, additional size separation of the aerosols may be needed, further increasing losses of precious test materials,” says Dr. Gerde.

Nose-only or intratracheal exposure

,Separating the system into three modular units; aerosol generator, aerosol dispensing system, and several different exposure modules, delivers other unique benefits. The dispensing unit can deliver quality aerosol to a range of different exposure modules with high precision and active dosing control, a versatility few platforms have. PreciseInhale is the only system on the market that allows for intratracheal or nose-only exposures of the same species, both delivered individually with precision dosing.

inhalation-tables-2

Active dosing increases research control and reduces costs

With PreciseInhale researchers can set and customize the dose. It is the only inhalation development technology that allows this.

“This is the only platform that can deliver active dosing,” says Dr. Per Gerde. “Doses can be individually controlled based on aerosol concentration and animal ventilation. With active dosing the single-animal exposure method exposes one animal at a time. This allows you to schedule your post-exposure treatment far more cost-effectively, exactly the way you want it. Substance consumption for a full PK study is typically less than 100 mg.”

Precision dosing produces world-class quality data

The quality and detail of the data produced with active dosing means researchers can choose with greater confidence which Candidate Drugs to continue with and which to eliminate long before entering the regulatory bodies.

“Our data has unsurpassed quality. Active dosing allows animal groups to be reduced to a minimum – while still delivering detailed data supported by our low standard deviation exposure methods. The quality of our data helps researchers achieve GLP level requirements already during the selection process of the most promising candidate drugs.”

inhalation-tables-3

Clinical use

Presently PreciseInhale is succeeding as a preclinical solution. But the versatility and value of the system is expected to lead to significant progress in early human clinical trials too. As a clinical solution PreciseInhale would offer human subjects the same kind of active, individual dosing, flexibility and versatility, and provide the same high-quality results.

“I think the system has huge potential and will inevitably transition successfully to clinical use,” says Dr. Gerde. “The opportunities for inhalation as a modality are enormous. PreciseInhale will deliver the same benefits for early human testing as it does for preclinical testing. Flexibility and increased control – the system can be used not only for first-in-man exposures but also later in formulation optimization before choosing the most appropriate clinical inhaler. And just as with the preclinical technology PreciseInhale offers precise and active dosing delivering extremely high-quality data.”